Compare BIRK & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BIRK | GPCR |
|---|---|---|
| Founded | 1774 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.3B |
| IPO Year | 2023 | 2023 |
| Metric | BIRK | GPCR |
|---|---|---|
| Price | $34.22 | $46.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 11 |
| Target Price | $62.69 | ★ $103.36 |
| AVG Volume (30 Days) | ★ 2.1M | 870.4K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.71 | N/A |
| Revenue Next Year | $14.21 | N/A |
| P/E Ratio | $17.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.06 | $13.24 |
| 52 Week High | $57.39 | $94.90 |
| Indicator | BIRK | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 37.69 | 26.76 |
| Support Level | $33.06 | $18.36 |
| Resistance Level | $42.19 | $61.20 |
| Average True Range (ATR) | 1.56 | 3.05 |
| MACD | -0.19 | -0.31 |
| Stochastic Oscillator | 20.50 | 9.86 |
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.